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ABSTRACT Immune control of human immunodeﬁciency virus type 1 (HIV) infection is
typically associated with effective Gag-speciﬁc CD8 T-cell responses. We here focus on
HLA-B*14, which protects against HIV disease progression, but the immunodominant
HLA-B*14-restricted anti-HIV response is Env speciﬁc (ERYLKDQQL, HLA-B*14-EL9). A sub-
dominant HLA-B*14-restricted response targets Gag (DRYFKTLRA, HLA-B*14-DA9). Using
HLA-B*14/peptide-saporin-conjugated tetramers, we show that HLA-B*14-EL9 is substan-
tially more potent at inhibiting viral replication than HLA-B*14-DA9. HLA-B*14-EL9 also
has signiﬁcantly higher functional avidity (P  0.0001) and drives stronger selection
pressure on the virus than HLA-B*14-DA9. However, these differences were HLA-B*14
subtype speciﬁc, applying only to HLA-B*14:02 and not to HLA-B*14:01. Furthermore, the
HLA-B*14-associated protection against HIV disease progression is signiﬁcantly greater
for HLA-B*14:02 than for HLA-B*14:01, consistent with the superior antiviral efﬁcacy of
the HLA-B*14-EL9 response. Thus, although Gag-speciﬁc CD8 T-cell responses may usu-
ally have greater anti-HIV efﬁcacy, factors independent of protein speciﬁcity, including
functional avidity of individual responses, are also critically important to immune control
of HIV.
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IMPORTANCE In HIV infection, although cytotoxic T lymphocytes (CTL) play a poten-
tially critical role in eradication of viral reservoirs, the features that constitute an ef-
fective response remain poorly deﬁned. We focus on HLA-B*14, unique among HLAs
associated with control of HIV in that the dominant CTL response is Env speciﬁc, not
Gag speciﬁc. We demonstrate that Env-speciﬁc HLA-B*14-restricted activity is sub-
stantially more efﬁcacious than the subdominant HLA-B*14-restricted Gag response.
Env immunodominance over Gag and strong Env-mediated selection pressure on
HIV are observed only in subjects expressing HLA-B*14:02, and not HLA-B*14:01. This
reﬂects the increased functional avidity of the Env response over Gag, substantially
more marked for HLA-B*14:02. Finally, we show that HLA-B*14:02 is signiﬁcantly
more strongly associated with viremic control than HLA-B*14:01. These ﬁndings indi-
cate that, although Gag-speciﬁc CTL may usually have greater anti-HIV efﬁcacy than
Env responses, factors independent of protein speciﬁcity, including functional avid-
ity, may carry greater weight in mediating effective control of HIV.
KEYWORDS CD8 T cells, HIV, HLA-B*14, immune control
Spontaneous durable control of HIV is observed in a rare subgroup (1%) of infectedindividuals known as “elite controllers” (1). Nonprogressive HIV infection is associ-
ated with expression of certain HLA class I molecules (2, 3), such as HLA-B*57 and
HLA-B*27 alleles (1, 4, 5). An important mechanism underlying the HLA associations
with HIV disease outcome is related to the particular HIV-speciﬁc epitopes presented by
different HLA class I molecules. In particular, “protective” HLA molecules typically
present broad Gag-speciﬁc epitopes to CD8 T cells, whereas disease-susceptible
alleles such as HLA-B*35:01 and HLA-B*58:02 present Nef- and Env-speciﬁc epitopes,
respectively, eliciting CD8 T-cell responses that are typically associated with poor
immune control of HIV (6–10).
Factors contributing to improved immune control in association with broad Gag and
not Nef or Env responses include the sequence conservation especially of the capsid
protein, because the cost to viral replicative capacity of Gag escape mutants is often
signiﬁcant (11–14). In contrast, Env escape mutants, for example, are typically tolerated
by the virus without signiﬁcant impact on viral replicative capacity (15). In addition, Gag
capsid proteins are much more abundant than Env trimers in mature virions (1,000 to
1,500 per virion versus 10 to 20, respectively) (16), and Gag epitopes can be presented
within 2 h of HIV gaining entry into the target cell, prior to de novo HIV protein synthesis
(17). Hence, HIV-infected cells can be killed by Gag-speciﬁc CD8 T cells before new
virion production (17, 18). In contrast, Nef- and Env-speciﬁc CD8 T-cell responses kill
virus-infected target cells only after de novo synthesis of viral proteins (17–20) and
therefore following Nef-mediated HLA class I downregulation (21, 22). Nonetheless,
Gag-speciﬁc CD8 T-cell responses are not equally efﬁcacious (6, 23, 24), and there is
evidence from the simian immunodeﬁciency virus (SIV)/macaque model that certain
non-Gag epitopes, for example, within Nef and Vif, are important for immune control
(25).
Furthermore, it is clear that several factors other than HIV protein speciﬁcity can play
an important role in the efﬁcacy of an epitope-speciﬁc response. These include func-
tional avidity (26, 27), polyfunctionality (28), lytic granules (29), and proliferative capac-
ity (30).
To investigate further the potential role of non-Gag-speciﬁc CD8 T-cell responses
in control of HIV infection, we focused here on HLA-B*14, where the dominant
HIV-speciﬁc CD8 T-cell response is in Env (31, 32). The association between HLA-B*14
and immune control of HIV has not been well studied to date (33), since most studies
of elite controllers have focused on those expressing HLA-B*27 or -B*57 (26, 29, 30,
34–38). Although HLA-B*14 is not as strongly associated with HIV disease progression
as HLA-B*27 or HLA-B*57, nonetheless, large studies have consistently shown a signif-
icant protective effect (3, 39–41). In addition to the dominant Env-speciﬁc CD8 T-cell
response, HLA-B*14-positive individuals also make a subdominant Gag-speciﬁc CD8
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T-cell response (42). We set out to investigate the role of these two speciﬁcities in
HLA-B*14-mediated suppression of HIV and to understand the mechanisms underlying
the observed differential antiviral activity among HLA-B*14-restricted CD8 T-cell
speciﬁcities.
RESULTS
Higher antiviral potency of B*14:02-Env-EL9 than of -Gag-DA9 CD8 T-cell
response. The starting point for this study was an elite controller subject, subject 1,
who ﬁrst tested HIV positive in the United Kingdom in 2011, having previously had two
negative tests in 2005 and 2008 (Fig. 1A). Since the positive HIV test, subject 1
maintained an undetectable viral load (VL; 40 copies/ml) and healthy and stable
CD4 T-cell counts (median, 1,555 cells/mm3; interquartile range [IQR], 1,345 to 1,788).
Viral sequencing revealed that she was infected with subtype B virus. HLA genotyping
showed that she was HLA-B*14:02/HLA-C*08:02 homozygous and also expressed an-
other HLA molecule, HLA-A*74:01, associated with slow disease progression (43).
To investigate the role that HLA-B*14:02-restricted CD8 T-cell responses might play
in immune control of HIV, we ﬁrst screened peripheral blood mononuclear cells (PBMC)
in this individual for HIV-speciﬁc gamma interferon (IFN-) enzyme-linked immunosor-
bent spot (ELISPOT) assay responses using overlapping peptides spanning the entire
HIV proteome (39) together with previously deﬁned HIV-speciﬁc epitopes (44). The
HLA-B*14:02-restricted responses dominated overall, the highest-magnitude responses
being those to the HLA-B*14:02-restricted Env-EL9 (584ERYLKDQQL592) (31) and its
corresponding overlapping peptide Env-366 (579RVLAIERYLKDQQLLGIW596) (Fig. 1B and
C). The next highest optimal peptide response was toward the HLA-B*14:02-Gag-DA9
epitope (298DRFYKTLRA306) (42).
To test the hypothesis that suppression of HIV in this patient was mediated
principally by HLA-B*14:02-restricted CD8 T-cell activity, we next compared the
antiviral potencies of Env-EL9- and Gag-DA9-speciﬁc CD8 T cells. From this same elite
controller (subject 1), bulk CD8 T cells were ﬁrst expanded with the bispeciﬁc CD3.4
antibody (45–47) and then depleted of selected CD8 T-cell speciﬁcities using cytotoxic
saporin (SAP)-conjugated tetramers (tet-SAP; see Materials and Methods) (Fig. 1D). The
ability of the bulk or depleted cytotoxic T lymphocytes (CTL) to inhibit viral replication
in vitro was then evaluated using T1 cells expressing HLA-B*14:02 as CD4 T-cell targets
and the B clade NL4-3 as the test strain of HIV (Fig. 1E and F). Removal of the Env-EL9
speciﬁcity substantially reduced the HIV-suppressive capacity of the expanded CD8 T
cells (22% of target cells infected versus 0.001% [Fig. 1E]), and suppressive capacity was
reduced by 26-fold (bulk CD8, 3.85 log10, versus Env-EL9-depleted CD8, 0.15 log10)
(Kruskal-Wallis, P  0.02) (Fig. 1F). In contrast, depletion of Gag-DA9-depleted cells
made little impact. This result suggests that the presence of Env-EL9 speciﬁcity repre-
sents the majority of CD8 T-cell-mediated control of viral suppression in subject 1 and
that the Gag-DA9 speciﬁcity does not contribute signiﬁcantly.
A potential caveat of this ﬁnding in this study subject is the unequal frequency of
Env- and Gag-speciﬁc CD8 T cells, with Env-speciﬁc cells being nearly 20-fold more
frequent than Gag-speciﬁc cells (Fig. 1D). To address this matter, we adopted two
approaches. First, we repeated targeted depletion experiments using cells from another
chronically B-clade-infected HLA-B*14:02-positive controller (subject 2, viral load [VL],
80 copies/ml; CD4, 1,355 cells/mm3), who had equal frequencies of Env-EL9- and
Gag-DA9-speciﬁc CD8 T cells (Fig. 1G, left panels). As with subject 1, elimination of the
Env-EL9 speciﬁcity resulted in preservation of 25% of infected target cells at the peak
of viral replication compared to only 1% in bulk CD8 T-cell coculture (Fig. 1H),
representing a 16-fold reduction (1.6 log10 versus 0.1 log10) of suppressive capacity of
the Env-EL9-depleted CTL (Kruskal-Wallis, P  0.03) (Fig. 1I). In contrast, Gag-DA9
depletion had only a minor effect, thus supporting the notion that Env-EL9-speciﬁc CTL
mediate the major antiviral efﬁcacy of the two HLA-B*14:02-restricted responses.
In the second approach, we tested the antiviral efﬁcacy of Env-EL9- and Gag-DA9-
speciﬁc CD8 T cells directly by generating epitope-speciﬁc CTL lines and clones. In the
HLA-B*14:02-Env-Restricted CD8 T Cells in HIV Control Journal of Virology
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experiments using peptide-speciﬁc lines (Fig. 2A to C), once again Env-EL9-speciﬁc CTL
were signiﬁcantly more potent at suppressing viral replication at the same effector-to-
target ratio of 1:100 (P  0.02) (Fig. 2B and C). Similarly, Env-EL9-speciﬁc CTL clones
were more potent inhibitors of viral replication than were Gag-DA9 clones. This was
particularly evident at the lower effector-to-target ratios (1:1,000) (Fig. 2D to F). Taken
together, these experiments suggest that Env-EL9-speciﬁc CD8 T cells are more
efﬁcacious at suppressing HIV replication than Gag-DA9-speciﬁc cells.
Higher functional avidity, antigen recognition, and magnitude of EL9 than of
DA9. In order to further investigate this observed antiviral superiority of Env-EL9-
FIG 1 Higher antiviral potency of B*14:02-EL9 than of -DA9 CD8 T-cell response. (A) HIV-related clinical proﬁle of subject 1; gray area shows time period during
which infection occurred. All viral load measurements were undetectable (40 copies/ml) and are shown below the limit of detection (LOD) of 40 copies/ml
for convenience. (B) CD8 T-cell IFN- ELISPOT responses to overlapping peptides (OLPs) spanning the entire HIV proteome in subject 1. The dotted line shows
the cutoff magnitude (50 SFC/106 PBMC). (C) CD8 T-cell IFN- ELISPOT responses to epitopes restricted by HLA class I alleles expressed by subject 1.
HLA-A*36:01-restricted responses are not shown as these are not deﬁned. The dotted line shows the cutoff magnitude (50 SFC/106 PBMC). (D to F) Data for
subject 1. (G to I) Data for subject 2. (D and G) Tetramer stainings conﬁrming HLA-B*14-02-Env-EL9 (top panels) and HLA-B*14:02-Gag-DA9 (bottom panels)
CD8 T-cell responses in bulk (left panels) and tetramer-depleted (right panels) cultures. Gated on live CD3 CD4 lymphocytes around CD8 tetramer cells;
numbers indicate percentage of CD8 cells. (E and H) Viral replication (percent GFP cells) time course in infected T1-HLA-B*14:02-positive target cells with
or without effector CD8 T cells. Results were compared to T1-HLA-B*14:02 target cells only at the peak of viral replication using paired t tests. (F and I)
Suppressive capacity of bulk Env-EL9-depleted or Gag-DA9-depleted effector cells calculated as described in Materials and Methods. Signiﬁcance was
determined by Kruskal-Wallis test with Dunn’s multiple-comparison test. (E, F, H, and I) Error bars represent standard errors of the means. *, P  0.05; **, P 
0.01; ***, P  0.001. Only signiﬁcant differences are shown. The color key applies to panels E, F, H, and I.
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speciﬁc cells over Gag-DA9-speciﬁc cells, we next examined the functional avidity of the
two speciﬁcities (determined by the peptide concentration required for 50% maximal
recognition [EC50]), the response magnitude, and the frequency of epitope recognition
in a larger number of HLA-B*14-positive subjects (n 30). Among all HLA-B*14-positive
subjects, functional avidity, or antigen sensitivity (EC50), of the Env-EL9 response was
24-fold higher than that of the Gag-DA9 response (median, 0.84 versus 20.3 M; P 
0.0001) (Fig. 3A, left panel). This difference was signiﬁcant among both HLA-B*14:01-
positive (median, 3.7 versus 21.3 M; P  0.003) and HLA-B*14:02-positive (median, 0.3
versus 19.8 M; P 0.0001) (Fig. 3A, right panel) subjects. However, Env-EL9 functional
avidity was 12-fold higher in HLA-B*14:02-positive subjects than in HLA-B*14:01-
positive subjects (P  0.005) (Fig. 3A, right panel).
The magnitude of the Env-EL9 response was also 9-fold higher than that of the
Gag-DA9 response among all HLA-B*14-expressing subjects among responders (P 
0.003) (Fig. 3B, left panel). This difference was signiﬁcant only among HLA-B*14:02-
positive subjects (Fig. 3B, right panel). Additionally, HLA-B*14:02-positive subjects had
a signiﬁcantly higher magnitude of the Env-EL9 response than the HLA-B*14:01-positive
subjects (P  0.03). Interestingly, the magnitude of both Env-EL9 and Gag-DA9 re-
sponses was negatively correlated with EC50 (i.e., positively with functional avidity)
(Env-EL9, r  0.73, P  0.0002; Gag-DA9, r  0.88, P  0.0001) (Fig. 3C), indicating
that cells with higher functional avidity mounted a response of greater magnitude.
Together, these data demonstrate that the greater antiviral potency of the HLA-
B*14-Env-EL9-speciﬁc response observed above is also associated with higher func-
tional avidity and response magnitude than those of the Gag-DA9-speciﬁc response.
Differential Env-EL9 and Gag-DA9 selection pressure in B*14:01 versus B*14:
02. To further understand the differences between Env-EL9- and Gag-DA9-speciﬁc
CD8 T-cell functions, we next investigated what selection pressure is imposed on the
virus by these two responses (Fig. 4). Consistent with previously published data
describing HLA-associated polymorphisms from analysis of 3,754 HLA-typed treatment-
naive persons (48, 49) within the Env-EL9 epitope (Fig. 4A), K588Q is strongly selected
FIG 2 Suppressive capacity of epitope-speciﬁc Env and Gag CTL lines and clones. (A to C) Results for CTL lines, generated by peptide stimulation of
epitope-speciﬁc cells from PBMC, with sorting and further expansion before testing in inhibition assays. (D to F) Examples of clones, generated by single-cell
sorting epitope-speciﬁc cells and growing them out in culture before testing their antiviral capacity. (A and D) Conﬁrmatory tetramer stainings of
epitope-speciﬁc CTL lines (A) and clones (D). Gated on live CD3 CD4 cells around CD8 tetramer cells; numbers indicate percent tetramer cells (of CD3
CD4 cells). (B and E) Viral replication in infected T1-HLA-B*14:02-positive target cells with or without effector cells. Results were compared to T1-HLA-B*14:02
target cells only at the peak of viral replication using paired t tests. *, P  0.05; **, P  0.01; ***, P  0.001, ns, not signiﬁcant (P  0.05). (C and F) Suppressive
capacity of effector cells. Signiﬁcance was determined by Mann-Whitney U test. (B, C, E, and F) Error bars represent standard errors of the means. The color key
in panel B applies also to panels C, E, and F. E:T, effector/target ratio.
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among both HLA-B*14:01- and HLA-B*14:02-positive persons, and variants at Env-588
and at other residues within Env-EL9 are observed more commonly in HLA-B*14:02-
positive subjects (although here these differences between HLA-B*14:01 and HLA-
B*14:02 did not reach statistical signiﬁcance) (Fig. 4B). These Env-EL9 sequence data
indicate stronger selection pressure imposed on the virus by the HLA-B*14:02-EL9
response than by the HLA-B*14:01-restricted EL9 response.
To put these Env-EL9 variants arising in HLA-B*14-expressing individuals into the
context of variation within this epitope overall, the frequency of Env-EL9 variants in B-
and C-clade infection in all subjects (https://www.hiv.lanl.gov) is 50% and 34%, respec-
tively, the most frequent variants being K558R (29% and 9% in B- and C-clade
FIG 3 Higher functional avidity and magnitude of EL9- than of DA9-speciﬁc response. (A) Functional avidity (EC50) of Env-EL9
versus Gag-DA9 CD8 T-cell responses in all HLA-B*14-positive subjects (n  30, left panel) or separately in HLA-B*14:01-
expressing (n  16) or HLA-B*14:02-expressing (n  14) subjects (right panel). Lines and numbers indicate median values.
Signiﬁcance was determined by Mann-Whitney U tests. (B) Magnitude of Env-EL9 or Gag-DA9 responses determined by IFN-
ELISPOT assay in all HLA-B*14-positive subjects (n  30; left panel) or in HLA-B*14:01-expressing (n  16) and HLA-B*14:02-
expressing (n  14) subjects (right panel). Numbers above the bar graphs indicate median values; error bars show interquartile
ranges. Signiﬁcance was determined by Mann-Whitney U tests. (C) Correlation between response magnitude and functional avidity
in HLA-B*14-positive (left), HLA-B*14:01-positive (middle), and HLA-B*14:02-positive subjects. r and P values were obtained by
Spearman correlation. The color key for all panels is shown in panel A.
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sequences, respectively) and K588Q (8% and 16%, respectively). Thus, K588R is rela-
tively common and, as shown in Fig. 4A, is not an HLA-B*14:01 or HLA-B*14:02 footprint
and indeed is not selected without accompanying variants in any of the subjects
studied here, whereas K588Q is selected in 17/35 (49%) HLA-B*14-positive subjects
studied here and in 17/25 (68%) of those whose autologous virus encoded Env-EL9
variants.
For the Gag-DA9 epitope, as shown in previous large cohort studies (48–50), the
most frequent K302R variant is selected only in HLA-B*14:01-positive subjects (P 
0.01). Thus, there was signiﬁcantly more variation in HLA-B*14:02-positive subjects in
the Env-EL9 epitope than in Gag-DA9 (P  0.001) (Fig. 4B), consistent with this being
the dominant response among HLA-B*14:02-positive subjects. Among B*14:01-positive
subjects, the Env-EL9 epitope was not targeted signiﬁcantly more than Gag-DA9, and
correspondingly, there was no signiﬁcant difference in the selection of variants within
Env-EL9 and Gag-DA9 in these subjects.
Selection of K588Q and not K588R is an escape variant in HLA-B*14-positive
subjects. The Env-EL9 sequence data shown above conﬁrm previous studies showing
that K588Q at position 5 (P5) in the epitope and binding in the D pocket of the
HLA-B*14 peptide-binding groove (51) is an HLA-B*14 footprint but K588R is not (48).
This is surprising, given the relatively frequent occurrence of Arg/Lys substitutions as a
mechanism by which HIV can escape recognition by other CTL speciﬁcities. Indeed, the
HLA-B*14:01-associated escape variant within Gag-DA9 is a case in point, K302R being
the substitution characteristically selected at P5 in the epitope.
In order to address this question, the ability of Env-EL9-speciﬁc CD8 T cells to
cross-react with the K588Q and with the K588R variants was analyzed in 8 HLA-B*14-
FIG 4 Differential Env-EL9 and Gag-DA9 selection pressure in B*14:01 versus B*14:02. (A) Consensus
sequences of Env-EL9 and Gag-DA9 epitopes and polymorphisms associated with HLA-B*14 subtypes;
overlapping polymorphisms associated with non-HLA-B*14 alleles are also shown. Data compiled from
previously published large cohort studies (48–50). (B) Frequency of Env-EL9 and Gag-DA9 wild-type and
variant sequences in the studied HLA-B*14-positive subjects. Graphs at the bottom compare frequencies
of subjects with autologous wild-type (ﬁlled bars) or mutated (empty bars) sequence of Env-EL9 versus
Gag-DA9 epitopes. Signiﬁcance was determined by Fisher’s exact tests. (A and B) Residues identical to the
wild type are presented as dashes; nonidentical residues are speciﬁed.
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positive subjects for whom samples were available. In 6 of 8 subjects, the autologous
variant was K588Q, and in the remaining two, autologous virus encoded wild-type (wt)
Env-EL9. The pattern of cross-recognition observed was quite distinct for the two
variants K588Q and K558R. For K588Q, in all 8 subjects, the frequency of cross-reactive
cells, double stained by EL9-wt and EL9-K558Q tetramers, was substantially lower than
the frequency of EL9-wt-speciﬁc CD8 T cells (Fig. 5). In all cases, including the 6 in
whom the K588Q variant had been selected, EL9-wt-speciﬁc responses were readily
detectable and in 5 of 8 cases were greater in magnitude than the EL9-K588Q-speciﬁc
response. In contrast, in most of these subjects (6 of 8), the frequency of CTL cross-
reactive for EL9-wt and K588R was higher than that of EL9-wt-speciﬁc CTL. Indeed, in
6 of these 8 subjects the K588R variant-speciﬁc response was higher than the EL9-wt-
speciﬁc response.
These results would explain why K588R is not selected as an escape mutant, since
the EL9-wt-speciﬁc response typically cross-reacts strongly with the K588R variant. In
contrast, the K588Q variant is not cross-recognized, and therefore, this mutant would
carry a selective advantage for the virus.
Impact of Gag-DA9 and Env-EL9 escape mutants on viral ﬁtness and HIV
outcome. Previous studies have indicated that the most effective CTL responses are
those capable of driving the selection of escape mutants that signiﬁcantly reduce viral
FIG 5 K588Q and not K588R is an escape variant in HLA-B*14-positive subjects. (A) Representative example of responses to EL9 wild-type versus EL9 K588Q
variant peptides at different peptide concentrations by IFN- ELISPOT assay. The example shown is subject OX018, who has an autologous EL9 K588Q variant.
(B) Cross-recognition of EL9 wild type and EL9 K588Q (top panels) versus EL9 wild type and EL9 K588R (bottom panels). The example shown is subject OX018,
who has an autologous EL9 K588Q variant. (C) Cross-reactivity data of wild-type EL9-speciﬁc cells with K588Q and K588R variants for 8 H:A-B*14-positive subjects
determined by tetramer staining.
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replicative capacity (11–14). These are more likely in p24 Gag, which is highly con-
served, than in Env, which is highly variable. We next, therefore, investigated the impact
on viral replicative capacity of the most common escape mutants in p24 Gag-DA9 and
Env-EL9 (Fig. 6A and B). In contrast to the general observation of the high cost of p24
Gag mutants, the K302R mutant had little impact on viral replicative capacity (VRC),
consistent with previous studies of this variant (52). The Env-EL9 mutant marginally but
not signiﬁcantly decreased VRC. Thus, in this particular case, the ﬁtness cost resulting
from the selection of escape mutants within the capsid protein appears to have little
impact on viral replicative capacity.
HLA-B*14-positive subjects who had wild-type Env-EL9 had lower viral loads (me-
dian of 9,068 versus 21,546 copies/ml, P 0.05) (Fig. 6C) and higher CD4 T-cell counts
(median of 606 versus 455 cells/mm3, P  0.005). Again, this difference was exclusive
to HLA-B*14:02-positive subjects, among whom individuals with wild-type Env-EL9 had
lower VLs than did those with a variant (median of 80 versus 20,003 copies/ml, P 0.04)
(Fig. 6D and E) and a trend toward higher CD4 T-cell counts (median of 1,340 versus
410 cells/mm3, P  0.2), although there were only three subjects with wild-type
sequence.
Taken together, these results suggest that the Env-EL9 response is highly effective
and contributes to successful immune control of HIV, whereas Gag-DA9 is not.
Stronger association of HLA-B*14:02 than HLA-B*14:01 with HIV immune con-
trol. On the basis of the ﬁndings above, if the B*14-Env-EL9 response makes a
signiﬁcant contribution to immune control of HIV, one would predict greater protection
against HIV disease progression in association with HLA-B*14:02 than with HLA-B*14:01.
To test this hypothesis, we ﬁrst compared the frequency of HLA-B*14:01 with that of
HLA-B*14:02 in viremic controllers (viral load of 2,000 copies/ml) versus noncon-
trollers (viral load of10,000 copies/ml) derived from several previously well-described
FIG 6 Impact of Gag-DA9 and Env-EL9 escape mutants on viral ﬁtness and HIV infection outcome. (A)
Replication kinetics of NL4-3 containing wild-type p24 and Env compared to the C-clade version of
Gag-DA9 epitope and three other HLA-B*14-associated Gag and Env mutants. Infectivity is expressed as
percent GFP-positive GXR reporter cells over 7 days after infection. Error bars represent standard errors
of the means. (B) Viral replication capacity of the viruses in panel A. Signiﬁcance was determined by
ANOVA with Dunnett’s multiple-comparison test comparing NL4-3 with the other viruses. Error bars
represent standard errors of the means. *, P  0.05; **, P  0.01; ***, P  0.001; ns, not signiﬁcant (P 
0.05). The color code is as in panel A. (C to E) Viral loads in HLA-B*14-positive (C), HLA-B*14:01-positive
(D), and HLA-B*14:02-positive (E) subjects with either wild-type or mutated autologous sequences in
Env-EL9 and Gag-DA9 epitopes. x axes indicate patients’ autologous epitope sequences. Only signiﬁcant
P values (P  0.05), obtained by the Mann-Whitney U test, are shown. Horizontal bars indicate medians.
wt, wild type; var, variant sequence.
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cohorts (see Materials and Methods). Although there was a trend toward HLA-B*14:02
being more protective than HLA-B*14:01 among HLA-B*14-positive Caucasians (self-
identiﬁed as “white”; n  285) and HLA-B*14-positive African Americans (self-identiﬁed
as “black”; n  104), in neither group was the difference statistically signiﬁcant (Table
1). We then extended the analysis to all controllers and noncontrollers in our cohorts
(whites, n 3,259; blacks, n 1,745) by performing a regression analysis with stepwise
selection that included all HLA-B alleles having a frequency equal to or greater than
that of HLA-B*14:01 (HLA-B*14:01 frequency in whites, 2.42%; in blacks, 1.60%) (Table
2). HLA-B*14:02 showed a signiﬁcant independent protective effect in both whites
(odds ratio [OR], 0.44; P  2e7 in whites) and blacks (OR, 0.54; P  2e2 in blacks),
but HLA-B*14:01 did not in either group. These results are consistent with previous data
where HLA-B*14:02 was shown to confer protection in a logistic regression model that
TABLE 1 Frequency of HLA-B*14:01 versus HLA-B*14:02 among viremic controllers and noncontrollersa
Patient group, allele, and adjustment
No. of
controllers
No. of
noncontrollers
B*14:01 vs B*14:02
OR (95% CI) P value
HLA-B*14 (n  285) from 3,259 whites
B*14:01 23 54
B*14:02 78 130
Not adjusted 1.41 (0.80–2.47) 0.23
Adjusted for B*27, B*57 1.54 (0.86–2.77) 0.15
HLA-B*14 (n  104) from 1,745 blacks
B*14:01 7 21
B*14:02 30 46
Not adjusted 1.96 (0.74–5.17) 0.18
Adjusted for B*57, B*81 1.52 (0.56–4.13) 0.41
aART-naive chronically HIV-infected subjects were categorized as viremic controllers (viral loads of 2,000 copies/ml plasma) or noncontrollers (viral loads of 10,000
copies/ml plasma). Logistic regression was used to compute signiﬁcance (P values), OR, and 95% CI for the differences in frequency of HLA-B*14 subtypes in
controllers versus noncontrollers, with adjustment by HLA-B*57/27 expression.
TABLE 2 HLA-B*14:02 is signiﬁcantly enriched among viremic controllersa
Patient group and allele being
compared with others OR 95% CI P value
Whites (n  3,259)
B*57:01 0.25 0.20–0.32 2e31
B*27:05 0.34 0.26–0.45 2e15
B*52:01 0.40 0.25–0.63 7e5
B*14:02 0.44 0.32–0.60 2e7
B*13:02 0.47 0.33–0.67 3e5
B*40:02 0.48 0.31–0.75 1e3
B*08:01 1.66 1.28–2.13 1e4
B*38:01 1.66 1.04–2.66 3e2
B*40:01 1.76 1.24–2.50 2e3
B*07:02 2.04 1.60–2.60 8e9
Blacks (n  1,745)
B*57:03 0.15 0.11–0.21 2e29
B*81:01 0.20 0.12–0.33 1e10
B*39:10 0.22 0.11–0.45 2e5
B*57:01 0.41 0.19–0.91 3e2
B*27:05 0.44 0.21–0.91 3e2
B*14:02 0.54 0.32–0.90 2e2
B*07:02 1.45 1.01–2.09 4e2
B*53:01 1.51 1.12–2.03 7e3
B*35:01 1.92 1.29–2.86 1e3
B*15:10 2.27 1.33–3.89 3e3
B*58:02 2.63 1.51–4.59 6e4
B*45:01 4.10 2.36–7.13 6e7
aPresence or absence of individual HLA-B alleles that have a frequency equal to or greater than that of HLA-
B*14:01 was tested by logistic regression with stepwise selection. B*14:02 is highlighted in bold.
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included all HLA class I alleles with a phenotypic frequency of 2% (33) and with our
immunological ﬁndings.
DISCUSSION
This study investigated HIV control mediated by HLA-B*14. We showed that the
HLA-B*14-restricted Env-EL9-speciﬁc CD8 T-cell response was more efﬁcacious against
HIV than the Gag-DA9-speciﬁc response. In association with this, the Env-speciﬁc
response had signiﬁcantly greater function avidity, was more frequently targeted,
and was of higher magnitude than the Gag-speciﬁc response. We demonstrated that
the functional avidity for Env-EL9 was signiﬁcantly higher for responses restricted by
HLA-B*14:02 than for responses restricted by HLA-B*14:01. Finally, we showed a sig-
niﬁcantly stronger association between HLA-B*14:02 and protection against HIV disease
progression than with the protection mediated by HLA-B*14:01.
Higher anti-HIV efﬁcacy of Env- than of Gag-speciﬁc CD8 T-cell responses is unusual
and, in fact, unreported until the current study. Numerous studies have suggested that
Gag-speciﬁc CD8 T-cell responses are associated with better disease outcome in HIV
infection, are more efﬁcacious in control of HIV than other speciﬁcities, and are often
dominant responses in elite controllers (6, 10, 18, 53–64). However, our result is
consistent with studies showing that non-Gag responses can also mediate viral control.
In the macaque model of elite control, Env-, Nef-, and Vif-speciﬁc CD8 T-cell responses
have been shown to be dominant and efﬁcacious in viral clearance (25, 65, 66). In HIV
infection, a dominant HLA-B*57-restricted Nef response was present in an elite con-
troller, although the antiviral efﬁcacy of that response has not been evaluated (67).
Similarly, HLA-B*27:02, an allele associated with better protection than HLA-B*27:05 (P.
Goulder, unpublished data), restricts the dominant CD8 T-cell response in Nef, al-
though as described above its efﬁcacy remains to be determined. Furthermore, effec-
tive elimination of infected cells by Env-speciﬁc CD8 T cells, including HLA-B*14-Env-
EL9-restricted cells, has been reported in HIV infection (68, 69). Our ﬁnding of the
superior Env-speciﬁc antiviral efﬁcacy is also consistent with a recent study of HLA-
B*57/27-negative HIV elite controllers indicating that potent cytotoxic capacity (mea-
sured by granzyme B expression and infected cell elimination) of HIV-speciﬁc CD8 T
cells rather than the identity of the targeted epitope is the determining factor in
mediating successful control of infection (70).
The data presented here are consistent with previous studies suggesting that an
important factor contributing to antiviral efﬁcacy of CD8 T-cell responses is high
functional avidity (26, 27, 71, 72). Functional avidity of the Env-EL9 response was
24-fold higher than that of the Gag-DA9-speciﬁc response and correlated strongly
with response magnitude; the Env-speciﬁc response was also more frequently targeted
than the Gag-speciﬁc response (Fig. 3). Thus, HLA-B*14-Env-EL9 CD8 T cells with
higher antigen sensitivity than HLA-B*14-Gag-DA9 cells would be expected to be more
efﬁcacious in controlling viral replication.
These qualitative differences between Env- and Gag-speciﬁc CD8 T cells were
signiﬁcant only among HLA-B*14:02-positive individuals (Fig. 3). In the case of
functional avidity, the difference between the Env- and Gag-speciﬁc responses was
signiﬁcant even among HLA-B*14:01-positive individuals, although less markedly
so. However, the avidity of the Env-EL9 response was still 12-fold higher in the
HLA-B*14:02-positive subjects than in the HLA-B*14:01-positive subjects. These obser-
vations suggest that despite restriction of the same epitopes by these two closely
related HLA-B*14 molecules, HIV-speciﬁc HLA-B*14:02-restricted CD8 T cells are qual-
itatively different from HIV-speciﬁc HLA-B*14:01-restricted CD8 T cells, and the differ-
ence is primarily determined by the superior function of HLA-B*14:02-restricted Env-
EL9-speciﬁc CD8 T cells.
It has previously been proposed that an important mechanism by which HLA class
I molecules inﬂuence rates of HIV disease progression is related to the speciﬁcity of the
particular HIV epitopes that are presented (8). As described above, factors other than
speciﬁcity are important. However, the demonstration here of the HLA-B*14-EL9 re-
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sponse as both immunodominant among HLA-B*14-positive subjects and efﬁcacious in
suppressing HIV is consistent with previous observations of HLA-B*14 being associated
with protection against rapid HIV disease progression (3, 39, 41). The substantially
higher functional avidity of this Env-EL9 response among HLA-B*14:02- than HLA-B*14:
01-positive subjects is also consistent with the ﬁndings here that HLA-B*14:02 is
signiﬁcantly more protective against HIV disease progression than HLA-B*14:01.
These studies have focused on the two principal HLA-B*14-restricted HIV-speciﬁc
responses. We have not considered other HLA-B*14-restricted HIV-speciﬁc responses
since these are the only 2 that drive selection pressure on the virus (48). The labor-
intensive nature of the work and the consequently small number of subjects studied
here limit our concluding deﬁnitively that in all cases HLA-B*14-restricted Env-EL9-
speciﬁc CD8 T cells inhibit HIV replication more effectively than HLA-B*14-restricted
Gag-DA9-speciﬁc responses. In addition, sample availability precluded our comparing
the capacities of HLA-B*14:01-restricted CTL clones and HLA-B*14:02-restricted CTL
clones to inhibit viral replication.
Structurally, HLA-B*14:01 and HLA-B*14:02 differ only at position 11 (P11), with a
serine and an alanine, respectively (73). However, P11 is unlikely to explain the
difference in HIV control between the two HLA molecules, because of its “buried”
location in the 1 domain of HLA near the C pocket (74, 75), where it does not
contribute to interactions between HLA domains or with a peptide or T-cell receptor
(TCR), is not solvent accessible, and is of low variability (76, 77). The peptide-binding
motif for HLA-B*14:02 has previously been determined (51). Studies identifying HLA-
B*14-restricted epitopes reported only 2-digit HLA, thus not showing an HLA-B*14:01
motif explicitly (31, 42). However, due to the lack of signiﬁcant structural differences the
peptide-binding motif is likely to be the same for the two molecules.
On the other hand, the buried P11 may alter the conﬁrmation of the nearby 1
residues or affect upstream peptide processing (73). Of note, HLA-B*14:02 and HLA-
B*14:03 differ by a single amino acid in the HLA sequence at P156 but share only30%
of their peptides (78). This single difference at P156, essential in D and E peptide-
binding pockets (76), may play a role in the differential association of HLA-B*14:02 and
HLA-B*14:03 with ankylosing spondylitis (78, 79). Previous HIV-speciﬁc studies have also
shown that one amino acid difference between HLA subtypes, such as HLA-B*35:01 and
HLA-B*35:03 (80), or HLA-B*35:01 and HLA-B*35:08 (81), HLA-B*42:01 and HLA-B*42:02
(24), and HLA-B*57:02 and HLA-B*57:03 (82), is sufﬁcient to have a signiﬁcant impact on
disease outcome.
Another distinguishing feature between HLA-B*14:01 and HLA-B*14:02 alleles ap-
pears to be in the selection pressure that they exert on the virus. First, the Gag-DA9
K302R mutation was found exclusively in HLA-B*14:01-positive subjects, consistent with
previous large cohort studies involving3,500 study subjects (48, 49). This again would
point to the lack of antiviral efﬁcacy of HLA-B*14:02-Gag-speciﬁc CD8 T cells. At the
same time, HLA-B*14:02 appeared to have selected the Env-EL9 K588Q mutation, and
there is a hint that this selection is associated with higher viremia and lower CD4 T-cell
counts (Fig. 6C to E). Curiously, however, neither of these mutations had a signiﬁcant
impact on viral replication, although Env-EL9-K588Q tended to have a slightly lower
replicative capacity than the wild type, while the opposite was true for Gag-DA9-K302R
(Fig. 6). This is particularly interesting in the case of the Gag epitope. This epitope (Gag
298 to 306) overlaps with the highly conserved major homology region (Gag 285 to
304) in the C terminus of HIV p24 capsid, which is essential for virion assembly and
stability (83, 84), and previous reports showed rapid reversion of K302R in the absence
of HLA-B*14:01 (50, 85), implying that K302R inﬂicts a signiﬁcant cost to viral replicative
capacity. However, the apparent lack of impact of this mutation on viral replication was
also recently reported by another group (52).
It is perhaps surprising that previous large studies investigating the relationship
between HLA class I type and HIV disease progression did not identify the difference
between HLA-B*14:02 and HLA-B*14:01 in terms of the protective effect conferred. In
some earlier studies, 2-digit HLA typing was employed (41), which prevented these
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analyses being undertaken. Also, HLA-B*14 class I subtypes are not especially prevalent,
especially in African populations (the phenotypic frequency of HLA-B*14 is 6.0% versus
8.7% in the present study [Tables 1 and 2]), and hence, large study numbers are needed
to achieve adequate statistical power. The current analysis involved 3,259 whites and
1,745 blacks, and even with these numbers, the protection afforded by HLA-B*14:02 in
the blacks was evident only at a P value of 0.02.
In conclusion, these studies indicate that, although Gag-speciﬁc CD8 T-cell re-
sponses may usually have greater antiviral efﬁcacy against HIV for the several reasons
described above, inﬂuences such as functional avidity of individual responses are also
critically important factors that may override protein speciﬁcity in contributing to
immune control of HIV infection. This ﬁnding is relevant to the development of vaccines
designed to generate effective antiviral CD8 T-cell responses.
MATERIALS AND METHODS
Study subjects. Adult chronically HIV-infected antiretroviral therapy (ART)-naive subjects studied
here were enrolled in the following cohorts: (i) Thames Valley cohort, United Kingdom (n  30) (18); (ii)
Gateway cohort, Durban, South Africa (n  17) (86); and (iii) the SCOPE (Study of the Consequences of
Protease Inhibitor Era) cohort, San Francisco, CA, USA (n  2) (87). Subjects from all cohorts provided
written informed consent, and the study was approved by the institutional boards of the University of
Oxford, the University of KwaZulu-Natal, and the University of California, San Francisco. HLA typing was
performed using a locus-speciﬁc PCR ampliﬁcation strategy and a heterozygous DNA sequencing
methodology for the HLA class I exon 2 and 3 amplicons. HIV plasma viral load measurements were done
using the Roche Amplicor version 1.5 assay with Cobas Amplicor (Thames Valley, Gateway, and SCOPE
cohorts) or using the Abbott RealTime HIV assay (SCOPE cohort). CD4 T-cell counts were enumerated
by ﬂow cytometry using standard clinical protocol. The median viral load of these study subjects was
9,700 copies/ml (IQR, 555 to 31,500); the median CD4 T-cell count was 527 cells/mm3 (IQR, 420 to 711).
To analyze the associations between the expression of HLA-B*14:01 and HLA-B*14:02 and immune
control of HIV, viral load and HLA data of the ART-naive chronically HIV-infected subjects (n  5,004;
Caucasians, n  3,259; African Americans, n  1,745) were used. These subjects were from the cohorts
from the following studies: AIDS Clinical Trial Group (ACTG) Study (https://actgnetwork.org), International
HIV Controllers Study (3) (http://www.hivcontrollers.org), Multicenter AIDS Cohort Study (MACS) (88)
(https://statepi.jhsph.edu/macs/macs.html), Multicenter Hemophilia Cohort Study (MHCS) (89) (https://
biolincc.nhlbi.nih.gov/studies/mhcs/), The Study of the Consequences of Protease Inhibitor Era (SCOPE)
(90) (https://hiv.ucsf.edu/research/scope.html), and the Swiss HIV Cohort Study (91) (www.shcs.ch).
Viremic controllers were deﬁned as individuals with viral loads of 2,000 copies/ml; noncontrollers
were deﬁned as individuals with viral loads of 10,000 copies/ml.
Tetramer generation and staining. Peptide-major histocompatibility complex (MHC) tetramers
conjugated to ﬂuorophores were generated as previously described, using streptavidin-phycoerythrin
(PE) or allophycocyanin (APC) (92). Cytotoxic saporin-conjugated tetramers were produced by the same
method using streptavidin-SAP (Advanced Targeting Systems) to tetramerize peptide-MHC monomers
according to the published approach (93). Brieﬂy, these modiﬁed tetramers are coupled to a toxin, the
ribosome-inactivating protein saporin (SAP), which can selectively kill antigen-speciﬁc cells of interest
and thereby evaluate the contribution of a particular CD8 T-cell speciﬁcity to viral inhibition (93–97).
The efﬁciency of tetramerization was conﬁrmed by staining with anti-mouse Ig  beads (BD Biosciences)
with an anti-HLA antibody, followed by tetramer staining. For staining with the ﬂuorescently conjugated
tetramers, PBMC or expanded CD8 T cells (0.5  106 to 1  106 cells per stain) were washed with
phosphate-buffered saline (PBS), incubated with relevant tetramers for 20 to 30 min at room temperature
in a 96-well U-bottom plate, washed again, further incubated with ﬂuorochrome-conjugated antibodies
for 15 min at room temperature, and ﬁxed in 2% formaldehyde solution at 4°C. For staining with
SAP-conjugated tetramers, cells were incubated with tetramers for 30 min at room temperature, washed,
ﬁxed and permeabilized with the BD Cytoﬁx/Cytoperm kit (BD Biosciences), and then incubated with a
secondary anti-SAP antibody (Alexa Fluor 488; Advanced Targeting Systems) as previously published (93).
Controls included cells incubated with no tetramer, HLA-mismatched SAP-conjugated tetramers, and free
unconjugated SAP. All samples were acquired within 6 h of staining on a MACSQuant Analyzer 10
(Miltenyi Biotec). Negative gates were set up using staining with no tetramer or with HLA-mismatched
tetramers. Samples were analyzed in FlowJo version 9.7.6 (Tree Star, Inc.) and hierarchically gated on
singlets, lymphocytes, live cells, and CD3 CD4 cells around CD8 tetramer-speciﬁc cell populations; in
viral inhibition assays, cells were gated on live CD4 green ﬂuorescent protein-positive (GFP) popula-
tions.
Selective depletion of antigen-speciﬁc CD8 T cells using cytotoxic tetramers. Antigen-speciﬁc
CD8 T cells were selectively depleted using cytotoxic saporin-conjugated tetramers (tet-SAP) as
described previously and conﬁrmed in our laboratory (93). First, CD8 T cells within PBMC were
expanded using a monoclonal CD3.4 antibody bispeciﬁc for CD3 and CD4 (the NIH AIDS Reagent
Program) which simultaneously eliminates CD4 T cells and expands CD8 T cells (45–47). Expanded
CD8 T cells were cultured in R10 medium (RPMI, 10% fetal calf serum [Sigma], 1% L-glutamine [Sigma],
and 1% penicillin-streptomycin [Sigma]), supplemented with 50 U/ml human premium-grade
interleukin-2 (IL-2; Miltenyi Biotec) (R10/50) for 10 to 14 days to achieve 90% purity. Expanded CD8
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T cells were then treated with tet-SAP (5 to 10 nM) for 2 h at 37°C, washed three times with R10, and
cultured in R10/50 for 24 to 48 h before they were used as effector cells in viral inhibition assays (see
below). Control treatments included HLA-mismatched tet-SAP, free saporin, or no treatment. Depletion
efﬁciency was conﬁrmed by tetramer staining prior to viral inhibition assay setup. tet-SAP-mediated
depletion was prevalidated by depleting antigen-speciﬁc cells using PE-conjugated tetramers and anti-PE
magnetic beads (StemCell Technologies).
Generation of polyclonal epitope-speciﬁc CD8 T-cell lines. Epitope-speciﬁc CTL lines were
generated as previously described (18) with modiﬁcations. Brieﬂy, fresh PBMC were peptide pulsed (2 
106 to 3  106 PBMC/peptide at 200-g/ml ﬁnal concentration) for 1 h and fed with fresh R10/50 every
2 to 3 days for 14 to 21 days. Speciﬁcity was tested by tetramer staining. To remove nonspeciﬁc cells,
tetramer-positive cells were sorted on a MoFlo XDP cell sorter (Beckman Coulter) and expanded in
R10/50 supplemented with monoclonal OKT3 antibody (eBioscience) at 0.1 g/ml. At the time of the
initial setup and every 10 to 14 days afterward, peptide-pulsed irradiated HLA-matched B cells and
irradiated feeder PBMC from three HIV-negative donors were added to the sorted cells at a 1:1:1 ratio.
The speciﬁcity and purity of expanded CD8 T cells were conﬁrmed by tetramer staining immediately
before using them as effector cells in viral inhibition assays.
Generation of CD8 T-cell clones. Epitope-speciﬁc clones were generated as previously described
(38). Brieﬂy, PBMC were stained with ﬂuorescently labeled tetramers. Tetramer-speciﬁc single cells were
sorted on a MoFlo XDP cell sorter (Beckman Coulter) directly into U-bottom 96-well plates (single
cell/well) in R10/50 containing monoclonal OKT3 antibody (eBioscience) at 0.1 g/ml. Twice a week, half
of the medium was replaced with fresh R10/50. After 2 to 3 weeks, cells were tested for their speciﬁcity
by tetramer staining. Epitope-speciﬁc clones were transferred to 48-well plates and then to 24-well
plates; at the time of transfer and/or every 14 to 21 days, clones were restimulated with monoclonal
OKT3, peptide-pulsed irradiated HLA-matched B cells, and irradiated feeder PBMC from three HIV-
negative donors.
Viral inhibition assays. To evaluate anti-HIV suppressive capacity of ex vivo unstimulated CD8 T
cells or stimulated epitope-speciﬁc CD8 T cells, we modiﬁed a previously described viral inhibition assay
(98). We used an HIV-permissive T1 cell line untransfected or transfected with the HLA-B*14:02 gene
(provided by Otto Yang; this cell line also expresses HLA-A*02, HLA-B*05, and HLA-B*06) (99) as target
cells. Effector cells were (i) “zapped” CD8 T cells, from which Env-EL9- or Gag-DA9-speciﬁc cells were
selectively depleted using tet-SAP as described above; (ii) CTL lines; and (iii) CD8 T-cell clones. For the
initial setup, target cells were infected with pretitrated NL4-3–GFP by spinoculation for 1 h, incubated at
37°C for 1 h, repeatedly washed, and further cultured with or without effector cells in duplicate or
triplicate. Every 2 to 3 days, cultures were fed and stained to assess live CD4 GFP cells. Percent GFP
uninfected target cells served as a background, subtracted from all values. HIV-suppressive capacity was
calculated at the time of the peak of viral growth as follows (98): suppressive capacity  log10(% GFP
infected target cells without effector cells/% GFP target cells with effector cells).
The viral inhibition assays shown were done using CTL lines and clones that were generated from 3
subjects.
Antibodies. Antibodies used were anti-CD3-brilliant violet 421 (UCHT1), anti-CD4-APC (OKT4),
anti-CD4-ﬂuorescein isothiocyanate (FITC) (OKT4) and anti-CD8-PE/Cy7 (RPA-T8) (BioLegend), anti-HLA-
APC (G46-2.6) (BD Biosciences), LIVE/DEAD ﬁxable near-infrared (IR) marker (Life Technologies), and
polyclonal chicken anti-saporin-Alexa Fluor 488 (Advanced Targeting Systems).
IFN- ELISPOT assays. Freshly isolated or cryopreserved PBMC were screened in IFN- ELISPOT
assays to quantify CD8 T-cell responses to a set of 410 overlapping 18-mer peptides spanning the HIV
proteome (6) and HLA-restricted optimal epitopes listed in the Los Alamos A-list of optimal HIV CTL
epitopes (100). ELISPOT assays were performed as previously described (101, 102). Spots were counted
using an automated ELISPOT reader (AID ELISPOT v4.0; Autoimmun Diagnostika, Germany). Positive
responses had to be at least three times the mean number of spot-forming colonies (SFC) in the four
control wells and 50 SFC/million PBMC after background subtraction. HIV peptides were produced by
Schafer-N.
Measurement of functional avidity. Functional avidity, or antigen sensitivity, was deﬁned as the
concentration of an exogenous peptide required to elicit half-maximal cellular response. Functional
avidity of CD8 T cells within PBMC was assessed in ex vivo IFN- ELISPOT assays by incubating 105 PBMC
per well with serial peptide dilutions over a range of 7 log10 units in triplicate. The peptides used were
wild-type Gag-DA9 and Env-EL9. ELISPOT assays were performed as described above.
Site-directed mutagenesis of NL4-3. Y301F, K302R, and Y301F/K302R mutations of HIV Gag
sequence as well as K588Q and K588R mutations in Env sequence were introduced, respectively, into the
HIV subtype B NL4-3 plasmid by using the QuikChange Lightning site-directed mutagenesis kit (Agilent
Technologies) along with custom-designed mutagenesis forward and reversed primers. The forward
primers are shown as follows (mutated codons shown in bold): 5=-C CTG GCT GTG GAA AGA TAC CTA
CAG GAT CAA CAG CT-3= (Env K588Q), 5=-GAC TAT GTA GAC CGA TTC TTT AAA ACT CTA AGA GCC
GAG-3= (Gag Y301F), 5=-T AGA GAC TAT GTA GAC CGA TTC TAT AGA ACT CTA AGA GCC G-3= (Gag K302R),
and 5=-A GAC TAT GTA GAC CGA TTC TTT AGA ACT CTA AGA GCC GAG CAA G-3= (Gag Y301F/K302R).
All mutations were conﬁrmed by sequencing.
Virus production and replication kinetics. All plasmids were maxiprepped according to the
manufacturer’s instructions (HiSpeed plasmid maxikit; Qiagen, Hilden, Germany). To generate mutant
viruses, the mutated NL4-3 Gag-Pro ampliﬁed puriﬁed PCR products with the BstEII (New England
BioLabs, Ipswich, MA)-linearized pNL4-3Δgag-protease were transfected into GFP reporter GXR cells via
electroporation in a Bio-Rad Gene Pulsar II using 0.4-cm cuvettes at 300 V, 500 F, and inﬁnite resistance
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(14). Virus propagation was then monitored by ﬂow cytometry (LSRII; BD Biosciences) to detect GFP-
expressing infected cells for 2 weeks in culture with GXR cells. Virus culture supernatants were harvested
when 30% of cells were GFP positive. Viruses were aliquoted and stored at80°C until use. All mutations
were conﬁrmed again by extracting viral RNA from the harvested supernatant and sequencing. Nucle-
otide similarity reached 99.99%. Along with wild type (wt) as positive controls and two negative controls
without viruses, NL4-3 mutant viruses were incubated with GXR cells in a 24-well plate for determination
of viral titers, as previously described (103). A low multiplicity of infection (MOI) (0.01%) was set as the
lowest threshold for determining the amount of virus required for inoculation. The GFP expression was
measured by ﬂow cytometry from days 2 to 7 before it reached the saturated 30 to 40%. The viral
replication capacity was deﬁned by the semilog calculation of the mean slope of exponential growth in
Excel. This was further calibrated to the normalized value relative to the wild-type NL4-3, respectively. All
assays were done at least in triplicate.
Ampliﬁcation and sequencing of proviral DNA. Genomic DNA was extracted from whole-blood
QIAamp reagents (Qiagen, United Kingdom), according to the manufacturer’s protocol. For the subjects
from the SCOPE cohort, whole blood was unavailable and DNA was extracted from cryopreserved PBMC
using the QIAamp DNA minikit according to the manufacturer’s protocol (Qiagen). HIV Gag and partial
Env (containing HLA-B*14-Env-EL9 584ERYLKDQQL592 epitope) segments were ampliﬁed by nested PCR,
as previously described (104), using the following primers: Gag-speciﬁc primers 5=-CTCTAGCAGTGGCG
CCCGAA-3= and 5=-TCCTTTCCACATTTCCAACAGCC-3= for the ﬁrst round (product size, 1,418 bp; HXB2
coordinates 627 to 2045) and 5=-ACTCGGCTTGCTGAAGTGC-3= and 5=-CAATTTCTGGCTATGTGCCC-3= for
the second round (product size, 1,307 bp; HXB2 coordinates 696 to 2003) and Env-speciﬁc primers
5=-GGAGATATAAGACAAGCACATTG-3= and 5=-CCCTGTCTTATTCTTCTAGGT-3= for the ﬁrst round (product
size, 1,579 bp; HXB2 coordinates 7194 to 8773) and 5=-GTGGAGGAGAATTTTTCTATTG-3= and 5=-CTATCT
GTTCCTTCAGCTACTGC-3= for the second round (product size, 1,349 bp; HXB2 coordinates 7357 to 8707).
PCR products were puriﬁed using the QIAquick PCR puriﬁcation kit (Qiagen, United Kingdom) according
to the manufacturer’s instructions. All sequencing was done using BigDye Terminator v3.1 Ready
Reaction mix (Applied Biosystems) as previously described (104) and analyzed using Sequencher v4.8
(Gene Codes Corp.). We generated maximum-likelihood trees of all sequences, using Mega6.06-mac
software and FigTree v1.4.2, to exclude the possibility of contamination with laboratory viral strains. HIV
subtypes were further conﬁrmed with NCBI (https://www.ncbi.nlm.nih.gov/guide/sequence-analysis/)
and REGA (http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/) HIV genotyp-
ing tools.
Statistical analysis. Statistical analyses were performed in GraphPad Prism for Mac OSX, 5.0c
(GraphPad Software). We used a paired t test to compare differences between remaining infected target
cells without effector cells and those with effector cells at the peak of viral replication; the Kruskal-Wallis
test with Dunn’s posttest (for 2-group analysis) or the Mann-Whitney U test (for 2-group analysis) to
analyze differences in HIV suppressive capacity; Fisher’s exact test to analyze differences in recognition
of Env-EL9 versus Gag-DA9 epitopes and in autologous sequences of Env-EL9 versus Gag-DA9 epitope;
the Mann-Whitney U test for differences in magnitude and functional avidity of Env-EL9 versus Gag-DA9
CD8 T-cell responses, in frequency of tetramer-speciﬁc cells in HLA-B*14:01- versus HLA-B*14:02-
positive subjects, and in viral load and CD4 T-cell counts; Spearman correlation to analyze the
correlation between response magnitude and functional avidity; and analysis of variance (ANOVA) with
Dunnett’s multiple-comparison test for differences in viral replicative capacity of different viral con-
structs. Functional avidity (EC50) was calculated in Prism using a dose-response function.
To analyze associations between HLA class I expression and HIV immune control, SAS 9.2 (SAS
Institute) was used. Genotype frequencies on individual HLA-B alleles were computed using PROC FREQ.
To calculate OR and 95% conﬁdence interval (CI) for viremic controllers versus noncontrollers with
adjustment by HLA-B*27 and HLA-B*57, PROC LOGISTIC was used; an OR of 1 indicates protection.
Presence versus absence of all individual HLA-B alleles that have a frequency equal to or greater than
HLA-B*14:01 was included in the models with stepwise selection.
Accession number(s). Sequences were deposited in GenBank under accession numbers MF445302
to MF445379.
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